Form 4: Halozyme Therapeutics Director Connie Matsui Reports Stock and Option Awards

Director Connie Matsui reports acquisition of stock and option awards from Halozyme Therapeutics.

Summary

• On April 25, 2024, Connie Matsui, a director of Halozyme Therapeutics, reported the acquisition of 6,501 shares of common stock and an option to purchase 8,804 shares of common stock.
• The 6,501 shares were received as an annual restricted stock unit (RSU) grant under the company's director compensation program.
• The RSU grant will vest fully on the earlier of April 25, 2025, or the date of the Issuer's next annual meeting of stockholders.
• The option to purchase 8,804 shares was also granted under the director compensation program with an exercise price of $38.46.
• This option grant will vest fully on the earlier of April 25, 2025, or the date of the Issuer's next annual meeting of stockholders.
• Following these transactions, Ms. Matsui beneficially owns 193,505 shares of Halozyme Therapeutics common stock and options to purchase 8,804 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The grants of stock and options to a director align her interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the grants.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies as part of executive and director compensation packages. These packages are designed to incentivize performance and align the interests of management with those of shareholders.

Comparison to Industry Standards

• Director compensation packages often include a mix of cash, stock, and options.
• Vesting schedules are standard practice to ensure long-term commitment.
• Companies like Amgen, Regeneron, and Gilead Sciences also utilize similar compensation structures for their directors.

Stakeholder Impact

• Shareholders may view the grants positively as they align the director's interests with the company's performance.
• Employees may see this as a standard part of the company's compensation practices.

Next Steps

• The director will need to monitor the vesting schedule of the RSU and stock option grants.
• The company will need to continue to disclose any changes in beneficial ownership.

Key Dates